Cargando…
Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus
Following primary infection in humans, the human cytomegalovirus (HCMV) persists in a latent state throughout the host’s lifetime despite a strong and efficient immune response. If the host experiences some form of immune dysregulation, such as immunosuppression or immunodeficiency, HCMV reactivates...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865657/ https://www.ncbi.nlm.nih.gov/pubmed/27242736 http://dx.doi.org/10.3389/fmicb.2016.00715 |
_version_ | 1782431816012005376 |
---|---|
author | Luganini, Anna Terlizzi, Maria E. Gribaudo, Giorgio |
author_facet | Luganini, Anna Terlizzi, Maria E. Gribaudo, Giorgio |
author_sort | Luganini, Anna |
collection | PubMed |
description | Following primary infection in humans, the human cytomegalovirus (HCMV) persists in a latent state throughout the host’s lifetime despite a strong and efficient immune response. If the host experiences some form of immune dysregulation, such as immunosuppression or immunodeficiency, HCMV reactivates, thereby emerging from latency. Thus, in the absence of effective functional immune responses, as occurs in immunocompromised or immunoimmature individuals, both HCMV primary infections and reactivations from latency can cause significant morbidity and mortality. However, even in immunocompetent hosts, HCMV represents a relevant risk factor for the development of several chronic inflammatory diseases and certain forms of neoplasia. HCMV infection may shift between the lytic and latent state, regulated by a delicate and intricate balance between virus-mediated immunomodulation and host immune defenses. Indeed, HCMV is a master in manipulating innate and adaptive host defense pathways, and a large portion of its genome is devoted to encoding immunomodulatory proteins; such proteins may thus represent important virulence determinants. However, the pathogenesis of HCMV-related diseases is strengthened by the activities of bioactive molecules, of both viral and cellular origin, that are secreted from infected cells and collectively named as the secretome. Here, we review the state of knowledge on the composition and functions of HCMV-derived secretomes. In lytic infections of fibroblasts and different types of endothelial cells, the majority of HCMV-induced secreted proteins act in a paracrine fashion to stimulate the generation of an inflammatory microenvironment around infected cells; this may lead to vascular inflammation and angiogenesis that, in turn, foster HCMV replication and its dissemination through host tissues. Conversely, the HCMV secretome derived from latently infected hematopoietic progenitor cells induces an immunosuppressive extracellular environment that interferes with immune recognition and elimination of latently infected cells, thereby promoting viral persistence. Characterization of the composition and biological activities of HCMV secretomes from different types of infected cells will lay the foundation for future advances in our knowledge about the pathogenesis HCMV diseases and may provide targets for the development of novel antiviral intervention strategies. |
format | Online Article Text |
id | pubmed-4865657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48656572016-05-30 Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus Luganini, Anna Terlizzi, Maria E. Gribaudo, Giorgio Front Microbiol Microbiology Following primary infection in humans, the human cytomegalovirus (HCMV) persists in a latent state throughout the host’s lifetime despite a strong and efficient immune response. If the host experiences some form of immune dysregulation, such as immunosuppression or immunodeficiency, HCMV reactivates, thereby emerging from latency. Thus, in the absence of effective functional immune responses, as occurs in immunocompromised or immunoimmature individuals, both HCMV primary infections and reactivations from latency can cause significant morbidity and mortality. However, even in immunocompetent hosts, HCMV represents a relevant risk factor for the development of several chronic inflammatory diseases and certain forms of neoplasia. HCMV infection may shift between the lytic and latent state, regulated by a delicate and intricate balance between virus-mediated immunomodulation and host immune defenses. Indeed, HCMV is a master in manipulating innate and adaptive host defense pathways, and a large portion of its genome is devoted to encoding immunomodulatory proteins; such proteins may thus represent important virulence determinants. However, the pathogenesis of HCMV-related diseases is strengthened by the activities of bioactive molecules, of both viral and cellular origin, that are secreted from infected cells and collectively named as the secretome. Here, we review the state of knowledge on the composition and functions of HCMV-derived secretomes. In lytic infections of fibroblasts and different types of endothelial cells, the majority of HCMV-induced secreted proteins act in a paracrine fashion to stimulate the generation of an inflammatory microenvironment around infected cells; this may lead to vascular inflammation and angiogenesis that, in turn, foster HCMV replication and its dissemination through host tissues. Conversely, the HCMV secretome derived from latently infected hematopoietic progenitor cells induces an immunosuppressive extracellular environment that interferes with immune recognition and elimination of latently infected cells, thereby promoting viral persistence. Characterization of the composition and biological activities of HCMV secretomes from different types of infected cells will lay the foundation for future advances in our knowledge about the pathogenesis HCMV diseases and may provide targets for the development of novel antiviral intervention strategies. Frontiers Media S.A. 2016-05-13 /pmc/articles/PMC4865657/ /pubmed/27242736 http://dx.doi.org/10.3389/fmicb.2016.00715 Text en Copyright © 2016 Luganini, Terlizzi and Gribaudo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Luganini, Anna Terlizzi, Maria E. Gribaudo, Giorgio Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus |
title | Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus |
title_full | Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus |
title_fullStr | Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus |
title_full_unstemmed | Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus |
title_short | Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus |
title_sort | bioactive molecules released from cells infected with the human cytomegalovirus |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865657/ https://www.ncbi.nlm.nih.gov/pubmed/27242736 http://dx.doi.org/10.3389/fmicb.2016.00715 |
work_keys_str_mv | AT luganinianna bioactivemoleculesreleasedfromcellsinfectedwiththehumancytomegalovirus AT terlizzimariae bioactivemoleculesreleasedfromcellsinfectedwiththehumancytomegalovirus AT gribaudogiorgio bioactivemoleculesreleasedfromcellsinfectedwiththehumancytomegalovirus |